Limits...
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer.

Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, Atula T, Ristimäki A, Haglund C - Br. J. Cancer (2011)

Bottom Line: Cytoplasmic CIP2A expression was higher in severe dysplasia than in mild dysplasia.Our results suggest that high CIP2A expression characterises aggressive disease.Acting as a prognostic marker it might be of help when choosing patients for adjuvant treatment in tongue cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Genome-Scale Biology Research Program, Biomedicum Helsinki, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 Helsinki, Finland.

ABSTRACT

Background: No reliable prognostic markers exist for squamous cell carcinoma of the tongue, and its prognosis can even in early stages be unpredictable and survival poor despite treatment. A potential marker is oncoprotein cancerous inhibitor of PP2A (CIP2A), which acts as a prognostic marker in gastric and non-small cell lung cancers.

Methods: We collected specimens of 73 stage T1N0M0 and T2N0M0 oral squamous cell carcinomas of the tongue, as well as samples from normal oral mucosa, dysplastic lesions, and invasive carcinomas (n=39). All samples were stained for CIP2A by immunohistochemistry. Survival curves were constructed according to the Kaplan-Meier method. The Cox proportional hazard model served for univariate and multivariate survival analysis.

Results: High CIP2A immunoreactivity predicted poor survival in tongue cancer patients (P=0.027, logrank test). In multivariate survival analysis, CIP2A was an independent prognostic factor (HR 2.02, 95% confidence interval 1.07-3.82, P=0.030). Cytoplasmic CIP2A expression was higher in severe dysplasia than in mild dysplasia.

Conclusion: Our results suggest that high CIP2A expression characterises aggressive disease. Acting as a prognostic marker it might be of help when choosing patients for adjuvant treatment in tongue cancer patients.

Show MeSH

Related in: MedlinePlus

Cytoplasmic CIP2A expression in tongue cancer specimens was scored as (A) negative, (B) moderately positive, and (C) strongly positive. Original magnification was × 200.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3111200&req=5

fig1: Cytoplasmic CIP2A expression in tongue cancer specimens was scored as (A) negative, (B) moderately positive, and (C) strongly positive. Original magnification was × 200.

Mentions: Cytoplasmic CIP2A immunoreactivity, tested in 73 cases, was negative in 2 (2.8%), weakly positive in 9 (12.7%), moderately positive in 28 (39.4%), and strongly positive in 32 (45.1%) cases. In the final analysis, negative to moderately positive CIP2A immunoreactivity (scores 0–2) was regarded as representative of low expression, whereas strongly positive CIP2A (score 3) represented high expression. Representative images of immunostaining are shown in Figure 1. High cytoplasmic CIP2A immunoreactivity was a marker of reduced overall survival with a 5-year survival of 59.4% (95% CI 42.4–76.4) for the patients with strongly positive CIP2A, compared with 74.4% (95% CI 60.7–88.1) for those with low CIP2A expression (logrank test, P=0.027; Figure 2A). For disease-specific survival, 5-year survival for patients with strongly positive CIP2A was 71.0% (95% CI 55.0–87.0) compared with 84.6% (95% CI 73.3–96.0) for patients with low CIP2A immunoreactivity (logrank test, P=0.038; Figure 2B).


High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer.

Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, Atula T, Ristimäki A, Haglund C - Br. J. Cancer (2011)

Cytoplasmic CIP2A expression in tongue cancer specimens was scored as (A) negative, (B) moderately positive, and (C) strongly positive. Original magnification was × 200.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3111200&req=5

fig1: Cytoplasmic CIP2A expression in tongue cancer specimens was scored as (A) negative, (B) moderately positive, and (C) strongly positive. Original magnification was × 200.
Mentions: Cytoplasmic CIP2A immunoreactivity, tested in 73 cases, was negative in 2 (2.8%), weakly positive in 9 (12.7%), moderately positive in 28 (39.4%), and strongly positive in 32 (45.1%) cases. In the final analysis, negative to moderately positive CIP2A immunoreactivity (scores 0–2) was regarded as representative of low expression, whereas strongly positive CIP2A (score 3) represented high expression. Representative images of immunostaining are shown in Figure 1. High cytoplasmic CIP2A immunoreactivity was a marker of reduced overall survival with a 5-year survival of 59.4% (95% CI 42.4–76.4) for the patients with strongly positive CIP2A, compared with 74.4% (95% CI 60.7–88.1) for those with low CIP2A expression (logrank test, P=0.027; Figure 2A). For disease-specific survival, 5-year survival for patients with strongly positive CIP2A was 71.0% (95% CI 55.0–87.0) compared with 84.6% (95% CI 73.3–96.0) for patients with low CIP2A immunoreactivity (logrank test, P=0.038; Figure 2B).

Bottom Line: Cytoplasmic CIP2A expression was higher in severe dysplasia than in mild dysplasia.Our results suggest that high CIP2A expression characterises aggressive disease.Acting as a prognostic marker it might be of help when choosing patients for adjuvant treatment in tongue cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Genome-Scale Biology Research Program, Biomedicum Helsinki, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 Helsinki, Finland.

ABSTRACT

Background: No reliable prognostic markers exist for squamous cell carcinoma of the tongue, and its prognosis can even in early stages be unpredictable and survival poor despite treatment. A potential marker is oncoprotein cancerous inhibitor of PP2A (CIP2A), which acts as a prognostic marker in gastric and non-small cell lung cancers.

Methods: We collected specimens of 73 stage T1N0M0 and T2N0M0 oral squamous cell carcinomas of the tongue, as well as samples from normal oral mucosa, dysplastic lesions, and invasive carcinomas (n=39). All samples were stained for CIP2A by immunohistochemistry. Survival curves were constructed according to the Kaplan-Meier method. The Cox proportional hazard model served for univariate and multivariate survival analysis.

Results: High CIP2A immunoreactivity predicted poor survival in tongue cancer patients (P=0.027, logrank test). In multivariate survival analysis, CIP2A was an independent prognostic factor (HR 2.02, 95% confidence interval 1.07-3.82, P=0.030). Cytoplasmic CIP2A expression was higher in severe dysplasia than in mild dysplasia.

Conclusion: Our results suggest that high CIP2A expression characterises aggressive disease. Acting as a prognostic marker it might be of help when choosing patients for adjuvant treatment in tongue cancer patients.

Show MeSH
Related in: MedlinePlus